Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Sage Bionetworks selected to establish new interdisciplinary research and training center

Sage Bionetworks has been selected by the National Cancer Institute Integrative Cancer Biology Program to establish a new interdisciplinary research and training center.

24 Feb 2010

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Today GenVec, Inc. announced a new contract with the Department of Homeland Security to continue the development of adenovector-based vaccines against foot-and-mouth disease (FMD) based on research and development done in collaboration with USDA-ARS and DHS S&T scientists at the Plum Island Animal Disease Center.

19 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

The good news is that there may soon be a new weapon in the battle against the so-called "worst" cancer - cancer of the pancreas. A multidisciplinary group of investigators from the UCLA School of Dentistry, the David Geffen School of Medicine at UCLA, the UCLA School of Public Health and UCLA's Jonsson Comprehensive Cancer Center has demonstrated the usefulness of salivary diagnostics in the effort to find and fight the disease.

17 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.

11 Feb 2010

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to provide clinical specimens to be utilized to complete the final validation of HDC's molecular diagnostic test for colon cancer. This test demonstrated a 93% Sensitivity and a 93% Specificity in a previous validation study.

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Celebrity promotes fundraising event fro cancer research

KIMBERLY WYATT from the "Pussycat Dolls" has shone brightly to promote Cancer Research UK's latest fundraising event by posing in a bespoke, illuminated dress designed especially for her

11 Feb 2010

Soft drinks increase risk of developing pancreatic cancer

Consuming two or more soft drinks per week increased the risk of developing pancreatic cancer by nearly two-fold compared with individuals who did not consume soft drinks, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

10 Feb 2010

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.

10 Feb 2010

Phase III BSD-2000 Hyperthermia System-chemotherapy combination study for pancreatic cancer initiated

BSD Medical Corporation reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1 surgical resection of their tumor (complete removal or only microscopic tumor remaining).

9 Feb 2010

Consuming two or more soft drinks per week may increase risk of developing pancreatic cancer

Consuming two or more soft drinks per week increased the risk of developing pancreatic cancer by nearly twofold compared to individuals who did not consume soft drinks, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

8 Feb 2010

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

Health Discovery Corporation announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avram Cooperman.

6 Feb 2010

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Solvay Pharmaceuticals, Inc. announced that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food.

5 Feb 2010

Study on the role of MCP-1 in obese patients with pancreatic cancer

The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.

4 Feb 2010

ACCP and FIRS honor World Cancer Day

During the 2010: The Year of the Lung campaign, the American College of Chest Physicians (ACCP) and other members of the Forum of International Respiratory Societies (FIRS) are honoring World Cancer Day, February 4, by elevating the awareness of lung cancer in terms of prevalence and prevention, as well as the amount of funding the disease receives for research in diagnosis and management.

4 Feb 2010

Pancreatic Cancer News and Research

Further Reading

Sage Bionetworks selected to establish new interdisciplinary research and training center

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Study demonstrates usefulness of salivary diagnostics in finding pancreatic cancer

Histone modifications associated with pancreatic cancer development and progression

Second-quarter fiscal 2010 results announced by Pharmacyclics

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

HDC signs agreement to receive clinical specimens for colon cancer molecular diagnostic test

CINJ researchers develop new vaccine strategy for pancreatic cancer

Celebrity promotes fundraising event fro cancer research

Soft drinks increase risk of developing pancreatic cancer

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Phase III BSD-2000 Hyperthermia System-chemotherapy combination study for pancreatic cancer initiated

Consuming two or more soft drinks per week may increase risk of developing pancreatic cancer

HDC partners with New York surgery center to develop new molecular diagnostic tests for pancreatic cancer

CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF

Study on the role of MCP-1 in obese patients with pancreatic cancer

ACCP and FIRS honor World Cancer Day

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News